Design Validation of Senofilcon A With New UV-blocking Additive

NCT03707821 | Completed Results FDA Device

• 1 other identifier: CR-6305
• Study Type: interventional
• Target: 253
• Locations: 1 country
• Sites: 10

Brief Summary

This is a 2-visit, multi-site, partially subject-masked, 2-arm parallel, controlled, randomized and dispensing trial. Subjects will be randomized to one of two study lenses for the entire duration of the study. The study lenses will be worn for a period of 2 weeks each in a bilateral fashion.

Conditions

Visual Acuity

Outcome Measures

Primary Outcomes (5)

• Overall Comfort Score

  Overall comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patientexperience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.

  2-Week Follow-up Evlauation

• Vision Satisfaction in Bright Lighting

  Vision satisfaction in bright light was assessed using the individual item" I was satisfied with the quality of my vision in bright lighting" from the CLUE™ questionnaire. This item used the response scale, 1: Strongly Disagree, 2: Disagree, 3: Neither Agree nor Disagree, 4: Agree and 5: Strongly Agree. CLUE is the Contact Lens User Experience™ questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120. The Proportion of responses in each category were reported for each lens type.

  2-Week Follow-up Evaluation

• Distance Visual Acuity

  Distance visual acuity was assessed by eye using LogMAR visual acuity at 4 meters using an ETDRS chart under high illumination high contrast conditions (room illumination \> 400 lux and chart luminance 120-200 cd/m2) at the 2-week follow-up for each subject eye. Lower values of logMAR indicate better vision, where a score of 0.0 equates to 20/20 snellen vision. The average visual acuity for each lens was reported.

  2-Week Follow-up Evlauation

• Contact Lens Fitting Acceptance Rate

  Acceptable lens fit will be assessed at all study visits (scheduled and unscheduled) for each subject eye. Fit acceptance rate will be based on the lens fit acceptance of eyes wearing the Test lens only. Fit acceptance is a binary response where Y=1 if lens fit is acceptable and Y=0 otherwise. Unacceptable is defined as unacceptable if any one of the following criteria: * limbal exposure at primary gaze or with extreme eye movement; * edge lift; * excessive movement in primary up gaze; * insufficient movement in all three of the following conditions: primary gaze, up gaze, and push up test. Eyes with multiple unacceptable fitting events will be counted only once. Fit rates of the Control lens will also be collected but are not a primary endpoint.

  Up to 2-Week Follow-up

• Number of Grade 3 or Higher Slit Lamp Findings

  Slit Lamp Findings (SLF) were assessed using a biomicroscope and was graded using the FDA grading scale (Grade: 0, 1,2, 3 and 4) with grade 0 represents the absence of findings and 1 to 4 representing successively worse findings (i.e. Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe). Slit Lamp Findings will be assessed for each subject eye at all study visits (schedule and unscheduled). SLF is a binary response where Y=1 for at least one Grade 3 or 4 slit lamp finding. The percentage of eyes with Grade 3 or higher slit lamp findings will be analyzed and will include corneal infiltrates. Eyes with multiple events will be counted only once. The number of eyes with SLF with grade 3 or higher by lens was reported.

  Up to 2-Week Follow-up Evlauation

Secondary Outcomes (2)

• Overall Handling Score

  2-Week Follow-up Evlauation

• Overall Quality of Vision Score

  2-Week Follow-up Evlauation

Study Arms (2)

senofilcon A TEST Lens

EXPERIMENTAL

Subjects between 18 to 49 years of age that are habitual wearers of spherical soft contact lenses will be randomized into the TEST Lens for the duration of the clinical study.

Device: senofilcon A TEST Lens

senofilcon A CONTROL Lens

ACTIVE COMPARATOR

Subjects between 18 to 49 years of age that are habitual wearers of spherical soft contact lenses will be randomized into the CONTROL Lens for the duration of the clinical study.

Device: senofilcon A CONTROL Lens

Interventions

senofilcon A TEST Lens DEVICE

JJVC Investigational Contact Lens

senofilcon A TEST Lens

senofilcon A CONTROL Lens DEVICE

Acuvue Oasys

senofilcon A CONTROL Lens

Eligibility Criteria

• Age: 18 Years - 49 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Potential subjects must satisfy all of the following criteria to be enrolled in the study:
• The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
• Appear able and willing to adhere to the instructions set forth in this clinical protocol.
• Between 18 and 49 (inclusive) years of age at the time of informed consent.
• Eligible presbyopes will be those that wear full distance contact lenses in both eyes, then wear reading glasses over them when needed for near vision.
• The subject is a current spherical soft contact lens wearer in both eyes with a minimum of 6 hours/day and 5 days/week wear time over the last 30 days by self-report.
• Subjects must be able and willing to wear the study lenses at least 6 hours a day, a minimum of 5 days per week.
• Subjects must own a wearable pair of distance spectacles.
• The subject's vertex-corrected spherical equivalent distance refraction must be in the range of -1.00 to -6.00 D (inclusive) in each eye.
• The subject's refractive cylinder must be 0.00 to -1.00 D (inclusive) in each eye.
• The subject must have a spherocylindrical best corrected distance Snellen visual acuity of 20/25+3 or better in each eye.

You may not qualify if:

• Potential subjects who meet any of the following criteria will be excluded from participating in the study:
• Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).
• Any active or ongoing systemic disease (e.g., Sjögren's Syndrome), infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g. rheumatoid arthritis).
• Subjects taking suspect oral medications for less than one year.
• Any prescribed or over the counter (OTC) ocular medication.
• Any known hypersensitivity or allergic reaction to Optifree® PureMoist® multi-purpose care solution or Eye-Cept® rewetting drop solution.
• Toric, extended wear, monovision or multi-focal contact lens correction.
• Any previous or planned (during the course of the study) ocular surgery (e.g., PRK, LASIK, etc.).
• Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment.
• Participation in clinical trials involving the Test lens within 3 months prior to study enrollment.
• Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician).
• Binocular vision abnormality or strabismus by self-report or prior medical history.
• History of recurrent corneal erosions, herpetic keratitis, or pathological dry eye.
• Any active ocular allergies, infections or other ocular abnormalities (entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma) that the investigator determines may interfere with the outcomes of this study or otherwise contraindicate participation in the study.
• Any Grade 2 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA Slit Lamp Classification Scale.

Sponsors & Collaborators

• Johnson & Johnson Vision Care, Inc.: lead

Study Sites (10)

James T. Fujimoto, OD

Cupertino, California, 95014, United States

Location

Maitland Vision Center

Maitland, Florida, 32751, United States

Location

Tallahassee Eye Center

Tallahassee, Florida, 32308, United States

Location

Eyecare Associates LLP

Bloomington, Illinois, 61701, United States

Location

Kannarr Eye Care

Pittsburg, Kansas, 66762, United States

Location

ProCare Vision Centers

Granville, Ohio, 43023, United States

Location

Professional Vision Care, Inc

Westerville, Ohio, 43081, United States

Location

Bradley Hines, OD

Memphis, Tennessee, 38111, United States

Location

Frazier Vision, Inc

Tyler, Texas, 75703, United States

Location

Ziegler Leffingwell Eyecare

New Berlin, Wisconsin, 53151, United States

Location

Results Point of Contact

• Title: John Buch OD, MS, FAAO Sr. Principal Research Optometrist
• Organization: Johnson & Johnson VIsion

JBUCH@its.jnj.com

9044431707

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: GT60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 12, 2018
• First Posted: October 16, 2018
• Study Start: October 1, 2018
• Primary Completion: November 1, 2018
• Study Completion: November 1, 2018
• Last Updated: December 5, 2019
• Results First Posted: December 5, 2019

Record last verified: 2019-11

Data Sharing

• IPD Sharing: Will not share

Locations

US (10)